Search Results - "Sánchez Lorenzo, Maria Luisa"

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry by Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lorenzo, Maria Luisa Sánchez, Ramchandani, Avinash, Martínez, Elena Asensio, Custodio, Ana, Garrido, Marcelo, Echavarría, Isabel, Cano, Juana María, Barreto, Jose Enrique Lorenzo, García, Teresa García, Manceñido, Felipe Álvarez, Lacalle, Alejandra, Cardona, Marta Ferrer, Mangas, Monserrat, Visa, Laura, Buxó, Elvira, Azkarate, Aitor, Díaz-Serrano, Asunción, Montes, Ana Fernández, Rivera, Fernando

“…There is currently no consensus regarding first-line chemotherapy for patients with advanced gastric cancer (AGC) who are ineligible to receive trastuzumab…”
Get more information

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer by Jiménez-Fonseca, Paula, Carmona-Bayonas, Alberto, Sánchez Lorenzo, Maria Luisa, Plazas, Javier Gallego, Custodio, Ana, Hernández, Raquel, Garrido, Marcelo, García, Teresa, Echavarría, Isabel, Cano, Juana María, Rodríguez Palomo, Alberto, Mangas, Monserrat, Macías Declara, Ismael, Ramchandani, Avinash, Visa, Laura, Viudez, Antonio, Buxó, Elvira, Díaz-Serrano, Asunción, López, Carlos, Azkarate, Aitor, Longo, Federico, Castañón, Eduardo, Sánchez Bayona, Rodrigo, Pimentel, Paola, Limón, Maria Luisa, Cerdá, Paula, Álvarez Llosa, Renata, Serrano, Raquel, Lobera, Maria Pilar Felices, Alsina, María, Hurtado Nuño, Alicia, Gómez-Martin, Carlos

“…Background Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced…”
Get full text

Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO by Yubero-Esteban, Alfonso, Reche-Molina, Piedad, Salvador Coloma, Carmen, Estévez-García, Purificación, Manso, Luis, Iglesias Campos, Marcos, Barquin, Arantzazu, Marquez, Raul, Santaballa, Ana, Calzas, Julia, Herrero, Ana, Casado, Victoria, Madani, Julia, Merino, Maria, Marquina, Gloria, Alarcon Company, Jesus, Gaba, Lydia, Fuentes Pradera, Jose, Gonzalez Martin, Antonio, Sanchez Lorenzo, Maria Luisa

“…e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer…”
Get full text

Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO by Yubero-Esteban, Alfonso, Barquin, Arantzazu, Gaba, Lydia, Iglesias Campos, Marcos, Reche-Molina, Piedad, Salvador Coloma, Carmen, Alarcon Company, Jesus, Manso, Luis, Marquez, Raul, Fuentes Pradera, Jose, Madani, Julia, Constenla Figueiras, Manuel, Gutierrez-Toribio, Maria, Estévez-García, Purificación, Santaballa, Ana, Sanchez Lorenzo, Maria Luisa, Calzas, Julia, Herrero, Ana, Taus, Alvaro, Gonzalez Martin, Antonio

“…e17562 Background: Rucaparib is a PARP inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). Clinical trials have demonstrated its benefit…”
Get full text

Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy by Mangas, Montserrat, Carmona Bayonas, Alberto, Sanchez Lorenzo, Maria Luisa, Ramchandani, Avinash, Garcia, Teresa, Custodio, Ana B., Lorenzo Barreto, Jose Enrique, Echavarria Diaz Guardamino, Isabel, Diaz Serrano, Asuncion, Cano, Juana Maria, Azkarate, Aitor, Longo, Federico, Mugica, Maitane, Sanchez, Rodrigo, Serrano, Raquel, Alvarez Manceñido, Felipe Jose, Alsina, Maria, Jiménez-Fonseca, Paula, Garrido, Marcelo, Gallego Plazas, Javier

“…Abstract only 142 Background: A prognostic model in advanced gastric cancer that integrates the Her2 status,histopathological classifications and other…”
Get full text